Sarepta Therapeutics (NASDAQ:SRPT) had its price target upped by Morgan Stanley from $165.00 to $220.00 in a research note released on Tuesday, BenzingaRatingsTable reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

A number of other research firms also recently issued reports on SRPT. BidaskClub raised shares of Misonix from a buy rating to a strong-buy rating in a research note on Wednesday, July 3rd. Piper Jaffray Companies reaffirmed a hold rating on shares of Seattle Genetics in a research note on Thursday, March 28th. HC Wainwright set a $267.00 target price on shares of Sarepta Therapeutics and gave the company a buy rating in a research note on Monday, June 17th. ValuEngine downgraded shares of WideOpenWest from a hold rating to a sell rating in a research note on Friday, June 28th. Finally, Credit Suisse Group set a $60.00 target price on shares of Oracle and gave the company a buy rating in a research note on Monday, March 11th. One investment analyst has rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Buy and a consensus target price of $206.82.

SRPT stock opened at $154.24 on Tuesday. Sarepta Therapeutics has a 1 year low of $95.21 and a 1 year high of $165.87. The company has a market capitalization of $11.20 billion, a P/E ratio of -28.25 and a beta of 2.12. The business has a 50-day moving average of $130.83. The company has a current ratio of 12.17, a quick ratio of 11.15 and a debt-to-equity ratio of 0.35.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 36.26%. The company had revenue of $87.01 million during the quarter, compared to the consensus estimate of $86.92 million. As a group, equities research analysts anticipate that Sarepta Therapeutics will post -4.04 earnings per share for the current year.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $120.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director now owns 21,717 shares of the company’s stock, valued at $2,606,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.60% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its position in shares of Sarepta Therapeutics by 3.8% during the first quarter. BNP Paribas Arbitrage SA now owns 2,676 shares of the biotechnology company’s stock valued at $319,000 after acquiring an additional 98 shares in the last quarter. American International Group Inc. increased its position in shares of Sarepta Therapeutics by 7.3% during the fourth quarter. American International Group Inc. now owns 1,605 shares of the biotechnology company’s stock valued at $175,000 after acquiring an additional 109 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Sarepta Therapeutics by 13.5% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,384 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 165 shares in the last quarter. Quad Cities Investment Group LLC increased its position in shares of Sarepta Therapeutics by 100.0% during the first quarter. Quad Cities Investment Group LLC now owns 400 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 200 shares in the last quarter. Finally, Focused Wealth Management Inc increased its position in shares of Sarepta Therapeutics by 2.5% during the first quarter. Focused Wealth Management Inc now owns 10,006 shares of the biotechnology company’s stock valued at $1,193,000 after acquiring an additional 240 shares in the last quarter. 94.36% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Featured Story: What is dollar cost averaging (DCA)?

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.